Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-07-05
2004-10-05
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S043000, C549S460000, C514S468000, C544S037000, C544S102000, C544S348000, C546S104000, C540S468000, C540S479000, C540S557000, C540S577000, C540S471000, C540S586000
Reexamination Certificate
active
06800656
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to compounds possessing antiviral activity against viruses of the herpes family, or a composition containing them. These compounds provide a method for treating herpes viral infections, including condition caused by herpes simplex I such as cold sores, herpes simplex II such as genital herpes, as well as shingles caused by herpes zoster and infections caused by cytomegalovirus, Epstein Barr Virus.
BACKGROUND OF INVENTION
Various subfamilies of herpes viruses (Herpes viridae) exist: &agr;-herpesvirinae, &bgr;-herpesvirinae, &ggr;-herpesvirinae and cercopithecing Herpes virus I (3 virus); some specific viruses are: Herpes simplex virus-I (HSV-1), Herpes simplex virus-2 HSV-2), Cytomegalovirus (CMV), Varicella Zoster virus (VZV), Epstein-Barr virus (EBV), human herpes virus-6 (HHV-6), human herpes virus-7 (HHV-7), human herpes virus-8 (HHV) as well as others which may not yet be defined.
The incidence of infections by Herpes simplex virus is very high throughout the world. Serological studies showed that herpes viral infections affect a substantial percentage of the population. Reactivation of herpes virus infections may lead to recurrent infections. The risk of severe diseases increases with decreasing immunocompetence of the host. There is a pressing need for improved therapy for treating this disease. Currently, exclusive of vaccines, treat involves primarily nucleoside drugs such as acyclovir, which target thymidine kinase and suffer from development of resistance.
SUMMARY OF THE INVENTION
The present invention provides a compound of the formula and its pharmaceutically acceptable salts, or the compound and its pharmaceutical composition having useful antiviral activity against viruses of the herpes family.
wherein:
X=O, (CH
2
)
m
, S, SO, SO
2
, NR
8
or a chemical bond;
Y=O, (CH
2
)
m
, S, SO, SO
2
, NH, NR
8
;
Z=N, NH, O, NHR
8
, S, SO, SO
2
;
n=an integer of from 0 to 2;
m=an integer of 1, 2, or 3;
R
1
, R
2
, R
3
, R
4
, R
5
independently are hydrogen, halogen, hydroxyl amino, mono or dialkylamino, cyano, nitro, alkyl groups (1-6 carbon atoms), alkoxy groups (1-6 carbon atoms), CF
3
, OCF
3
, aminoalkyl (1-6 carbon atoms), aminoaryl, Oaryl, or a heterocyclic ring having 5-7 atoms with 1-4 hetero atoms of N, O, or S;
Ar=phenyl,
substituted phenyl,
benzoheterocyclic ring,
substituted benzoheterocyclic ring,
heterocyclic ring, or
substituted heterocyclic ring, which have substitutions R
6
or R
7
;
R
4
and R
7
are independently hydrogen, alkyl group (1-6 carbon atoms), cycloalkyl (3-12 carbon atoms), halogen, alkoxy, CF
3
, aminoalkyl (1-6 carbon atoms), aminoaryl, or a heterocyclic ring of from 5-7 atoms with 1-4 heteroatoms of N, O or S;
R
6
and R
7
may also form a ring, optionally cycloalkyl or aryl or substituted aryl; R
8
is hydrogen, alkyl (1-6 carbon atoms), cycloalkyl (3-12 carbon atoms), phenyl or substituted phenyl wherein the substituents are as defined above.
The invention also provides for a pharmaceutical composition for the treatment of infection or disease caused by a virus, optionally a Herpes virus which comprises an amount of the compound of claim
1
sufficient to provide an antivirally effective dosage of the compound of Formula I and a pharmaceutically effective carrier.
The invention also provides for a method of treatment of infection or disease caused by a virus, optionally a Herpes virus which comprises administering to a subject in need of such treatment an effective antivirally dosage of a composition of formula I.
REFERENCES:
patent: 2990368 (1961-06-01), Thompson
patent: 3413291 (1968-11-01), Sparks
patent: 3592819 (1971-07-01), Fleming et al.
patent: 3673191 (1972-06-01), Albrecht et al.
patent: 3929802 (1975-12-01), Albrecht et al.
patent: 3932424 (1976-01-01), Albrecht et al.
patent: 5049464 (1991-09-01), Kanemaru et al.
patent: 19813979 (1999-09-01), None
patent: 863550 (1957-04-01), None
patent: 1040737 (1966-09-01), None
patent: 1268772 (1972-03-01), None
patent: 10101591 (1998-04-01), None
patent: WO 95/04723 (1995-02-01), None
patent: WO98/30544 (1998-07-01), None
Cecil Textbook of Medicine, 20th Edition, vol. 2, pp. 1739-1747.*
Dunkerton et al. (Journal of Heterocyclic Chemistry (1987), 24(3), 749-55).*
Hagen, et al., Synthesis of 6-substituted beta-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists, J. Med. Chem., 30:750-753 (1987).
Chemical Abstracts, vol. 128, No. 28 (1998).
Chemical Abstracts, vol. 94, No. 23 (1981).
Chemical Abstracts, vol. 36, No. 14 (1942).
Chemical Abstracts, vol. 63, No. 7 (1965).
Chemical Abstracts, vol. 127, No. 17 (1997).
Chemical Abstracts, vol. 77, No. 17 (1972).
Chemical Abstracts, vol. 111, No. 24 (1989).
Chemical Abstracts, vol. 108, No. 10 (1988).
Wang, et al., Hepatitis C Viral IRES Inhibition by Phenazine and Phenazine-Like Molecules, Bio & Medic Chem Ltrs 10:1151-1154 (2000).
International Search Report for PCT/US00/32571 filed on Nov. 30, 2000.
Booth Richard John
Josyula Vara Prasad Venkata Nagendra
Meyer Annette Lynn
Steinbaugh Bruce Allan
Berch Mark L.
Habte Kahsay
Neidert Karl
Richardson Peter
Warner & Lambert Company
LandOfFree
Tricyclic compounds and method of treating herpes virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tricyclic compounds and method of treating herpes virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic compounds and method of treating herpes virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3276251